Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Expert Rev Anticancer Ther. 2018 Sep;18(9):823–836. doi: 10.1080/14737140.2018.1503954

Figure 4. Patient experience with apalutamide in phase II study of patients with mCRPC. (A) AAP-naïve and (B) post-AAP (B) cohorts.

Figure 4

[43] These swim lane plots show the duration of apalutamide treatment from shortest (top lane) to longest (bottom lane) in the AAP-naïve and post-AAP mCRPC cohorts.

AAP: abiraterone acetate plus prednisone; PSA: prostate-specific antigen.

Source: Rathkopf et al., 2017[42]. Reprinted with permission.